Antengene Corporation Limited (HK:6996) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Antengene Corporation Limited has announced that the Thailand Food and Drug Administration approved its New Drug Application for XPOVIO® to treat multiple myeloma in certain adult patients, marking another milestone for the company’s expanding oncology portfolio in the Asia Pacific region. XPOVIO® is recognized as the first orally-available selective inhibitor of the nuclear export protein XPO1, and Antengene aims to continue its mission of ‘Treating Patients Beyond Borders’ with innovative cancer treatments. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
For further insights into HK:6996 stock, check out TipRanks’ Stock Analysis page.